EPZM News and Press, Epizyme Inc. From 06/16/21

EZH2Now Testing Program is first of its kind to offer national single gene testing for EZH2 Epizyme (Nasdaq: EPZM), a fully integrated, commercial-stage biopharmaceutical company developing and delivering novel epigenetic therapies, today launched the EZH2Now Testing Progr...

Constellation Pharmaceuticals ([[CNST]] +67.2%) has risen more than two-thirds in value after agreeing to be acquired by German biotech MorphoSys AG (MOR) in a deal valued at $1.7B.The offer price of $34.00 per share in cash for Constellation’s common stock indicates a premium of ...

Epizyme , (Nasdaq: EPZM), a fully integrated, commercial-stage biopharmaceutical company developing and delivering novel epigenetic therapies, today announced that Robert Bazemore, President and Chief Executive Officer, will participate in a fireside chat during the Jefferies Virtua...

Oral Presentation of Preclinical Data on Inhibition of SETD2, a Histone Methyltransferase, in Multiple Myeloma to be Presented at the European Hematology Association (EHA) Congress Poster Presentation for Tazemetostat, a Methyltransferase Inhibitor, in Epithelioid Sarcoma at the A...

Image source: The Motley Fool. Epizyme Inc (NASDAQ: EPZM) Q1 2021 Earnings Call May 6, 2021 , 7:30 p.m. ET Operator Continue reading For further details see: Epizyme Inc (EPZM) Q1 2021 Earnings Call Transcript

Gainers: InnSuites Hospitality Trust (IHT) +95%.Regional Health Properties (RHE) +30%.Cooper-Standard (CPS) +25%.MoneyGram International (MGI) +23%.Epizyme (EPZM) +21%.The L.S. Starrett (SCX) +21%.Clene (CLNN) +20%.Yield10 Bioscience (YTEN) +20%.Phio Pharmaceuticals (PHIO) +19%.Core...

Gainers: Regional Health Properties (RHE) +39%, Auris Medical (EARS) +26%, Clene (CLNN) +25%, Pro-Dex (PDEX) +20%, Epizyme (EPZM) +17%.Losers: ChemoCentryx (CCXI) -59%, Orphazyme (ORPH) -30%, F-star Therapeutics (FSTX) -21%, Aur...

iBio (IBIO) +33% on COVID-19 study update.Orgenesis (ORGS) +11% on Q1 results.Chemomab Therapeutics (CMMB) +12%.T2 Biosystems, Inc. (TTOO) +11% on Q1 results.ViewRay (VRAY) +12%.Epizyme (EPZM) +11% on Q1 results.CureVac N.V. (CVAC) +9%.Roku (ROKU) +9% on Q1 results.Da...

The following slide deck was published by Epizyme, Inc. in conjunction with their 2021 Q1 earnings call. For further details see: Epizyme, Inc. 2021 Q1 - Results - Earnings Call Presentation

Epizyme (EPZM): Q1 GAAP EPS of -$0.69 misses by $0.12.Revenue of $7.63M (+465.2% Y/Y) beats by $0.76M.2021 Financial GuidanceBased on its current operating plans, Epizyme expects its current cash runway to extend into 2023. Additionally, the Company expects its non-GAAP adjusted operating exp...